(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most exciting exoplanet discoveries of 2025 - 2Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- 3Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 18
- 4From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- 5Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Find Wonderful Stream Voyage Objections On the planet
- HGV driver recruited others to smuggle migrants
- Without evidence, CDC changes messaging on vaccines and autism
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- Find the Excellence of Old style Expressive dance: Encountering the Effortlessness and Polish of Dance
- The Best Internet based Courses for Expertise Improvement
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Hot Electric Vehicles for 2023
